Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters.
Journal
TheScientificWorldJournal
ISSN: 1537-744X
Titre abrégé: ScientificWorldJournal
Pays: United States
ID NLM: 101131163
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
10
2021
revised:
23
03
2022
accepted:
27
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Ebastine is a long-acting, nonsedating, second-generation antihistaminic drug that prevents histamine action, mainly in immediate hypersensitivity. This project was aimed to formulate and characterize orodispersible tablets of ebastine, utilizing different proportions of three disintegrants, namely crospovidone, sodium starch glycolate, and coprocessed superdisintegrant. Initially, fifteen trial batches of ebastine orodispersible tablets were outlined using the central composite design of Minitab software. The tablets were formulated by the direct compression method. The compressed tablets were then evaluated for precompression and postcompression physicochemical parameters, such as angle of repose, Carr's index, Hausner's ratio, hardness, thickness, weight variation, drug content, friability, wetting time, disintegration time, dispersion time, and water absorption ratio. The
Identifiants
pubmed: 35645632
doi: 10.1155/2022/9618344
pmc: PMC9135552
doi:
Substances chimiques
Butyrophenones
0
Piperidines
0
Tablets
0
Water
059QF0KO0R
Povidone
FZ989GH94E
ebastine
TQD7Q784P1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9618344Informations de copyright
Copyright © 2022 Bhawana Dhakal et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Drug Deliv. 2016 Oct;23(8):2998-3007
pubmed: 26828616
J Pharm Sci. 2016 Jun;105(6):1907-1913
pubmed: 27155767
J Pharm Sci. 1991 Dec;80(12):1153-6
pubmed: 1815074
Expert Rev Pharmacoecon Outcomes Res. 2008 Aug;8(4):337-42
pubmed: 20528340
Saudi Pharm J. 2014 Dec;22(6):570-9
pubmed: 25561871
Molecules. 2019 May 10;24(9):
pubmed: 31083285
Heliyon. 2021 Mar 15;7(3):e06439
pubmed: 33786387
J Adv Pharm Technol Res. 2011 Apr;2(2):128-31
pubmed: 22171305
AAPS PharmSciTech. 2007 Feb 02;8(1):9
pubmed: 17408231
AAPS PharmSciTech. 2018 Aug;19(6):2598-2609
pubmed: 29916193
J Control Release. 2005 Jun 20;105(1-2):16-22
pubmed: 15955365
Indian J Pharm Sci. 2010 Jan;72(1):130-3
pubmed: 20582206
Int J Prev Med. 2016 Oct 26;7:120
pubmed: 27857833
Crit Rev Anal Chem. 2018 Mar 4;48(2):102-109
pubmed: 29235880
Indian J Pharm Sci. 2014 Sep;76(5):423-9
pubmed: 25425756